Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts
- 15 August 2007
- journal article
- review article
- Published by Elsevier in Journal of Infection
- Vol. 55 (4) , 287-299
- https://doi.org/10.1016/j.jinf.2007.06.012
Abstract
No abstract availableKeywords
This publication has 148 references indexed in Scilit:
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Prophylaxis and Aspergillosis — Has the Principle Been Proven?New England Journal of Medicine, 2007
- Effects of Caspofungin against Candida guilliermondii and Candida parapsilosisAntimicrobial Agents and Chemotherapy, 2006
- The Evolution and Evaluation of a Whole Blood Polymerase Chain Reaction Assay for the Detection of Invasive Aspergillosis in Hematology Patients in a Routine Clinical SettingClinical Infectious Diseases, 2006
- Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 2004
- Review of Newer Antifungal and Immunomodulatory Strategies for Invasive AspergillosisClinical Infectious Diseases, 2003
- Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazoleClinical and Experimental Dermatology, 2001
- Mortality and Costs of Acute Renal Failure Associated with Amphotericin B TherapyClinical Infectious Diseases, 2001
- A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile NeutropeniaClinical Infectious Diseases, 2000